Fig. 6: HDAC depletion in CAFs reduces tumor progression in vivo.
From: Inhibiting stromal Class I HDACs curbs pancreatic cancer progression
a, b Estimated volumes (a) and representative images (D16 post-transplantation, b) from ultrasound imaging for orthotopic transplants of PDAC cells (p53 2.1.1) with or without CAFs transduced with shEV or shH1/2/3. Tumor boundaries are highlighted with dotted lines. c Transplant weights at the endpoint (D19). d, e Measurements of total α-SMA, Sirius Red (SR) and CK19 positive areas (d) and ratio of CK19+ and α-SMA+ areas (e) in whole transplant sections. f LIF abundance per mg transplant lysates measured by immunoassay. Transplant measurements (a, c), n = 5 (no CAF), 7 (shEV), 8 (shH1/2/3) transplants; staining quantifications (d, e), n = 7 (shEV), 8 (shH1/2/3) transplants; LIF immunoassay (f), n = 5 transplant lysates. Data are presented as mean values ± SEM. *p < 0.05, =0.033 (c, shH1/2/3 vs shEV), 0.025 (d, CK19+), 0.038 (f); **p < 0.01, =0.006 (a, shEV vs no CAF at D16), 0.004 (a, shH1/2/3 vs shEV at D16), 0.007 (c), 0.001 (d, α-SMA+); ***p < 0.001 (d, SR+). Two-sided t-test. Source data are provided as a Source Data file.
